Bristol Myers Squibb

I had the pleasure of taking part in the 2024 #HispanicLeadershipSummit at the United Nation in NYC through The Hispanic Star and the We Are All Human Foundation Claudia Romo Edelman. This multi-day Leadership Forum provided a platform to both celebrate the achievements of the Hispanic and Latino communities and to convene on the work still needed to elevate our voices. Among those in attendance were several of my Bristol Myers Squibb colleagues, including Lorena Kuri, global lead of the Organization for Latino Achievement (OLA) People & Business Resource Group and other OLA members. To be in the presence of fellow Hispanic and Latino leaders and allies with a centralized focus on unity, representation and goal setting has left me feeling grateful and energized for the new year. During the summit, I was honored to be on a panel to discuss the importance of authentic allyship and fostering partnerships with those who can use their influence to advocate on behalf of the Hispanic and Latino communities. This work is personal and enduring for me. I am deeply committed to advocating for those in need and driving progress through impactful actions for all underrepresented groups. I am so thankful for community spaces like the #HispanicLeadershipSummit. The work we do today is what will help ensure an even brighter, shiner and more unified future.   Thank you for having us. #HLS2024 #TogetherWeShine #HispanicProgress #Allyship #WeAreAllHuman #BMS_Employee #BuildingtheFutureTogether

Today, we announced topline results from two pivotal Phase 3 trials for an investigational medicine in adults with #PsoriaticArthritis. Our research underscores our commitment to following the science to help more patients with immune-mediated rheumatic diseases potentially achieve their treatment goals. Learn more about the topline results: https://bit.ly/4iHxO1o

We’re celebrating 10 years since bringing an important immunotherapy treatment option to cancer patients. As we look to the future in #Oncology, we remain committed to advancing cancer treatment through research and innovation. Thank you to those who have been instrumental in helping to make a meaningful difference in the lives of patients worldwide.

In 2024, our dedicated colleagues and partners around the world helped us reach new milestones for our patients. Watch highlights from the year and join in celebrating our achievements, from pursuing bold science and digital innovations to our #C2C4C riders who raised millions for cancer research. We look forward to the new year and giving more hope to more patients, together. #OneBMS

We are nearing the end of another transformative year, and I am proud to share our latest Climate Change Report, which highlights our ongoing commitment to sustainability and responsible innovation. 🌍   At Bristol Myers Squibb we recognize the critical role we play in addressing climate change and are dedicated to minimizing our environmental impact while advancing our mission to improve patient outcomes. This report underscores our strategic initiatives and achievements in reducing carbon emissions, enhancing energy efficiency, and fostering sustainable practices across our global operations to support climate resiliency.   I invite you to explore our Climate Change Report to learn more. Together, let’s continue to drive positive change and make a lasting impact.   Read the full report here: BMS Climate Change Report (https://lnkd.in/edhH3aGx)   #Sustainability #ClimateChange #ResponsibleBusiness #BMS_Employee

Last week, our Targeted Protein Degradation Forum in San Diego provided a valuable opportunity to engage with thought leaders on the latest advancements in #hematology. We are committed to transforming the treatment landscape for patients living with a broad range of hematological diseases, including multiple myeloma and lymphoma, as we continue to expand our discovery and development of novel protein degraders, and target disease-causing proteins previously considered “undruggable." Discover more about targeted protein degradation: https://bit.ly/3P3fF0w #ASH24 #TargetedProteinDegradation

How are we applying precision medicine to advance new #CardiovascularDisease (CVD) therapies? In a recent Q&A with Francisco Ramírez-Valle, MD, PhD, FAAD, he discusses how we’re drawing on decades of insights in genetics and causal human biology to discover and develop more individualized and effective options for people with living CVD. Learn more: https://bit.ly/3VFPHUx #OneBMS

Computational scientists like Ivy thrive as members of our Research teams, working alongside lab scientists to approach scientific questions with a wide range of lived experiences and expertise, to help discover and develop transformative medicines for patients. See how our collaborative culture advances our approach to science: https://bit.ly/4gdlILX #OneBMS

10,000 patients treated with our cell therapies: This milestone is more than a number—it reflects how we transform patients’ lives through science and the dedication of countless individuals working together to bring #CARTcelltherapy to life. Driven by our teams’ expertise and commitment to advancing care, we are asking “What if?” to challenging questions in pursuit of better outcomes for patients. We’re expanding access to cell therapy to deliver on the promise of innovation. Thank you to the patients, families and healthcare professionals who make this progress possible. Together, we’re shaping a brighter future for patients worldwide. https://bit.ly/3Dc6vfj #OnACellularLevel

Today we celebrate the completion of the 2024 #C2C4C Rides, which entailed hundreds of Bristol Myers Squibb employees cycling extraordinarily long distances across four continents to raise money to give hope to cancer patients through research. I’m proud to share that through these efforts, more than $2.2 million will be donated to local cancer charities around the world. Having participated in the #C2C4C rides, I know how tough this ride can be, and I am incredibly proud of this year’s team. The training and the ride itself take immense dedication – including time away from family and friends. The C2C4C Rides challenge the body and mind with waves of doubt, fear, triumph and joy.   Congratulations to our 2024 #C2C4C riders! You make BMS proud! #BMS_Employee #ProudToBeBMS